# Trichoderma harzianum fungemia following COVID-19-related immune dysregulation in an immunocompetent patient: a case diagnosed by mNGS

**Authors:** Lin Zhou, Yanling Xu, Li Wang, Xin Li

PMC · DOI: 10.1186/s12879-026-12568-4 · BMC Infectious Diseases · 2026-01-12

## TL;DR

A 68-year-old immunocompetent man developed Trichoderma harzianum fungemia after a COVID-19 infection, diagnosed using mNGS and successfully treated with posaconazole.

## Contribution

First documented case of T. harzianum fungemia in an immunocompetent patient following transient immune dysregulation from COVID-19.

## Key findings

- mNGS identified T. harzianum in blood with 794 reads when conventional tests were negative.
- Posaconazole effectively treated the infection, with symptoms resolving within seven days.
- No recurrence was observed during 12 weeks of follow-up.

## Abstract

Trichoderma harzianum is a filamentous saprophytic fungus rarely implicated in human infections. Invasive Trichoderma infections are uncommon and are typically observed in immunocompromised hosts.

We report a 68-year-old immunocompetent male farmer who developed persistent fever and dizziness after COVID-19 infection. Initial empirical antibacterial and antiviral therapy failed to relieve symptoms. Repeated blood cultures and serological fungal tests were negative, whereas metagenomic next-generation sequencing (mNGS) of whole blood identified T. harzianum sequences (794 reads), confirming fungemia. The patient experienced severe infusion reactions to amphotericin B and visual disturbances with voriconazole, but responded well to posaconazole therapy. Fever subsided within seven days, mNGS sequence reads declined markedly, and no recurrence occurred during 12 weeks of follow-up.

This case represents the first documented instance of T. harzianum fungemia in an immunocompetent individual following transient immune dysregulation associated with COVID-19. The report underscores the diagnostic value of mNGS in detecting rare opportunistic fungi when conventional cultures are negative and highlights posaconazole as a potential therapeutic option.

The online version contains supplementary material available at 10.1186/s12879-026-12568-4.

## Linked entities

- **Chemicals:** amphotericin B (PubChem CID 1972), voriconazole (PubChem CID 71616), posaconazole (PubChem CID 468595)
- **Diseases:** COVID-19 (MONDO:0100096)
- **Species:** Trichoderma harzianum (taxon 5544)

## Full-text entities

- **Diseases:** Trichoderma harzianum fungemia (MESH:D016469), COVID-19 (MESH:D000086382), immune dysregulation (OMIM:614878)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12888569/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12888569/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12888569/full.md

---
Source: https://tomesphere.com/paper/PMC12888569